

References for Appendix 2 –
Extravasation Potential of Various Chemotherapy/Supportive Agents

ASWCS Policy for the Treatment of Extravasation Injury. Avon Somerset and Wiltshire Cancer Services, July 2012.

Extravasation Hazard Table. BC Cancer Agency, May 21, 2015.

Leung M, Bland R, Baldassarre F, et al. Safe Administration of Systemic Cancer Therapy Part 2: Administration of Chemotherapy and Management of Preventable Adverse Events. Cancer Care Ontario and Program in Evidence-Based Care (Evidence-Based Series #12-12-2), March 2014. Available from:
<http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=299609>

Material Safety Data Sheet: Cabazitaxel. Sanofi-aventis, June 16, 2010.

Material Safety Data Sheet: Methotrexate. Hospira Inc., June 2, 2014.

Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012 Oct;23 Suppl 7:vii167-73.

Product monograph. Zaltrap™ (aflibercept). Sanofi-aventis Canada Inc., February 12, 2014.

Product Monograph: Emend® IV (fosaprepitant). Merck Frosst Canada, Jan 22, 2014.

Product Monograph: Bonefos® (clodronate). Bayer Inc., September 22, 2011.

Product Monograph: Halaven® (eribulin). Eisai Limited, January 2015.

Product Monograph: Alimta® (pemetrexed). Eli Lilly Canada Inc, May 10, 2013.

Product Monograph: Istodax® (romidepsin). Celgene Inc., May 30, 2014.

Product Monograph: Hycamtin® (topotecan). GlaxoSmithKline Inc., July 9, 2009.

Product Monograph: Zometa® (zoledronic acid). Novartis Pharmaceuticals Canada Inc. June 2014.